As illustrated in Table 3, the therapeutic possibilities of targeting N-glycan biosynthesis with safe and selective DPAGT1 inhibitors are vast, offering countless opportunities to explore novel strategies in cancer treatment [41,56,94,95,96,97,98,99,100,101,102,103]. Here, DPAGT1 is linked to cancer.